REG - OptiBiotix Health - Director Appointment and Director Dealing

OptiBiotix HealthAnnouncement

01/07/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220701:nRSA9002Qa&default-theme=true

RNS Number : 9002Q  OptiBiotix Health PLC  01 July 2022

OptiBiotix Health plc

("OptiBiotix", the "Group" or the "Company")

 

Director Appointment and Director Dealing

 

OptiBiotix Health plc (AIM:
OPTI), a life sciences business developing compounds to tackle obesity,
high cholesterol, diabetes and skin care, announces the appointment of René
Kamminga as a Director of the Company, with immediate effect and issue of
options as part of his appointment.  René is currently a Director and Chief
Executive Officer of OptiBiotix Ltd, the Company's wholly owned prebiotic
business.

 

Director appointment

René has more than 25 years' experience in the sale of speciality ingredients
and products and joined OptiBiotix Ltd in March 2021 (RNS: 23 March 2021) from
the position of Vice President of Business Development and Chief Commercial
Officer of the Nutraceuticals division of one of the world's largest Omega-3
and fish oil refiners KD Pharma Group. As Chief Commercial Officer, René was
integral in developing and delivering on a strategy of moving the business
from bulk ingredients to finished product solutions. Prior to joining KD
Pharma, René was President of Kerry Groups Texturants division with full
P&L responsibility for its speciality ingredient business in Europe. Prior
to this he worked in business director roles for Quest and Uniqema,
subsidiaries of Unilever and ICI.

 

Since his appointment to OpiBiotix Ltd, René has brought experience of
developing a business from selling bulk ingredients to finished product and a
wealth of industry contacts in both the pharmaceutical and nutraceutical
industries. He has a strong track record of rapidly growing sales and has been
involved in a number of acquisitions in support of accelerating business
growth. His experience of speciality food ingredients and high value final
product solutions will help drive the business expansion of OptiBiotix'
growing pipeline of microbiome modulation products and technologies.

 

René's appointment is part of a long-planned strategy to appoint experienced
industry business leaders to lead each part of the business allowing the Group
CEO to focus on identifying and developing new technologies and acquisition
opportunities. His appointment to the main Board is recognition of the
progress he has made in building OptiBiotix's prebiotic business.

 

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the
following information is disclosed in respect of René Kamminga (aged 55):

 

 Current Directorships  Directorships in the past five years
 OptiBiotix Limited     Kamminga Ventures BV
 Alsoka BV
 Kamminga Beheer BV
 Care by Nature BV

 

René Kamminga currently holds 55,844 shares in the Company, representing 0.06
per cent. of the Company's current issued share capital and options over
500,000 ordinary shares in the Company as part of the issue of options
detailed below.

There is no further information regarding René required to be disclosed under
the AIM Rules.

Director dealing and issue of options

As part of the OptiBiotix Share Option Plan, options over 500,000 new ordinary
shares have been granted to René Kamminga (the "Options"). The Options are
exercisable within 10 years at an exercise price of 2p per share, which will
be subject to a combination of performance and time-based vesting criteria.

 

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to welcome René
onto the Company's main Board in recognition of progress he has made in
building OptiBiotix's prebiotic business as CEO of OptiBiotix Ltd.  René's
experience and track record of growing sales and network of industry contacts
within the ingredients and nutraceutical industries will bring sector specific
expertise to the Board and support continued growth in this exciting area of
healthcare."

 

This announcement contains inside information for the purposes of the UK
Market Abuse Regulation and the Directors of the Company are responsible for
the release of this announcement.

 

For further information, please contact:

 

 OptiBiotix Health plc                                     www.optibiotix.com (http://www.optibiotix.com/)
 Stephen O'Hara, Chief Executive  Contact via Walbrook below

 Cairn Financial Advisers LLP (NOMAD)                      Tel: 020 7213 0880
 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Cenkos Securities plc (Broker)                            Tel: 020 7397 8900
 Callum Davidson / Neil McDonald
 Michael Johnson / Russell Kerr (Sales)

 Walbrook PR Ltd                                           Mob: 07876 741 001
 Anna Dunphy

 

Certain statements in this announcement, are, or may be deemed to be, forward
looking statements. Forward looking statements are identified by their use of
terms and phrases such as ''believe'', ''could'', "should" ''envisage'',
''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect",
''will'' or the negative of those, variations or comparable expressions,
including references to assumptions. These forward looking statements are not
based on historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of operations,
performance, future capital and other expenditures (including the amount,
nature and sources of funding thereof), competitive advantages, business
prospects and opportunities. Such forward looking statements reflect the
Directors' current beliefs and assumptions and are based on information
currently available to the Directors.]

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
 596/2014
 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name                                                         René Kamminga
 2   Reason for notification
 a.  Position/Status                                              Director
 b.  Initial notification/                                        Initial Notification

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         OptiBiotix Health Plc
 b.  LEI                                                          213800UKYQFT941QHS14
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument  Options over ordinary shares of 2p each

Identification Code

                                                                  ISIN: GB00BP0RTP38
 b.  Nature of the transaction                                    Issue of options over 500,000 ordinary shares as part of the Company Share
                                                                  Options Plan

 c.  Price(s) and volume(s)
                                                                                 Price(s) per share  Volume(s)
     2p                                                                          500,000

 d.  Aggregated information

     -       Volume                                               N/A

     -       Price
 e.  Date of the transaction                                      1 July 2022
 f.  Place of the transaction                                     London Stock Exchange, AIM

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHWPUACQUPPGAU